With sales of its existing drugs growing well, the biotech turns its eye to the approval of its Duchenne muscular dystrophy drug Kyndrisa (drisapersen), which should lead to profitability.
With sales of its existing drugs growing well, the biotech turns its eye to the approval of its Duchenne muscular dystrophy drug Kyndrisa (drisapersen), which should lead to profitability.